Below is a comprehensive archive of press releases from MSF-USA. Use the options in the boxes below to filter results based on your preferences.

August 22, 2017

Hopes for improved access to an affordable pneumococcal conjugate vaccine (PCV) that protects both children and adults from pneumonia was dealt a major blow after the Indian patent office granted a patent to the U.S. pharmaceutical corporation Pfizer.

June 27, 2017

A leaked draft of President Trump’s executive order on drug pricing reveals that the White House will perpetuate policies that have led to a broken biomedical research and development (R&D) system and raise drug prices around the world, said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF).

September 19, 2016

“After years of fighting for children caught in crises and desperately in need of the pneumonia vaccine, Doctors Without Borders/Médecins Sans Frontières is relieved to see that GlaxoSmithKline (GSK) finally plans to reduce its vaccine price for humanitarian organizations. GSK is leading the way in this commitment to children who are experiencing the most horrific of circumstances, while Pfizer continues to hide behind excuses and offer only piecemeal approaches to the humanitarian community.

April 27, 2016

MSF hands over global petition as volunteers place 2,500 flowers in front of Pfizer’s headquarters in New York, representing the number of kids who die of pneumonia each day.

March 11, 2016

New York/New Delhi—Doctors Without Borders/Médecins Sans Frontières (MSF) has filed a "patent opposition" in India to block US pharmaceutical company Pfizer from patenting a pneumococcal conjugate vaccine, and ensure affordable access to this critical vaccine (PCV13). This is the first time a vaccine (biosimilar) patent has been challenged in India by a medical organization and, if successful, will make affordable versions of this lifesaving vaccine available to developing countries and humanitarian organizations.

November 12, 2015

MSF dumps $17 million in fake cash at Pfizer’s New York HQ, the amount the company makes in one day of pneumonia vaccine sales.